other material
confidence high
sentiment neutral
materiality 0.55
Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate
Zivo Bioscience, Inc.
- Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.
- To date, completed exchanges with two investors for 14,200 shares of common stock.
- Director Laith Yaldoo manages two entities expected to participate in the Exchange Program.
- Exchange eliminates investor rights to future revenue share cash and a $5.3M buy-out option.
- Investors retain Warrants issued under the original Participation Agreements.